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Background: Recent studies show that a common gain-of-function polymorphism of `1-adrenergic receptor
(389 GlyAArg) plays an important role in the pathogenesis of hypertension and heart failure in patients with
normal renal function. We studied the relationship between `1-adrenergic receptor polymorphism and
cardiovascular disease in peritoneal dialysis (PD) patients.
Methods: We studied 189 new PD patients. The ` 1-adrenergic receptor genotype was determined by polymerase
chain reaction-restriction fragment length polymorphism assay. They were then prospectively followed for the
development of cardiovascular events. All-cause mortality and duration of hospitalization were also recorded.
Results: There were 95 male cases. The mean age was 56.2 ± 14.8 years. Eighty-six (45.5%) patients were
diabetic; 81 (42.9%) received beta-blocker therapy. Only one case was homozygous for the mutant CC genotype.
The prevalence of GG, GC, and CC genotypes were 34.9%, 64.6%, and 0.5%, respectively. The genotype
distribution was significantly different from that predicted by the assumption of Hardy-Weinberg equilibrium
(p < 0.0001). There was no difference in the prevalence of pre-existing cardiovascular disease between genotype
groups. Actuarial patient survival was 80.2% and 85.1% at 24 months for the GG and GC/CC genotypes,
respectively (p = 0.53). Event-free survival was 63.6% and 71.5% at 24 months, respectively (p = 0.26), and
the duration of hospitalization was 15.9 ± 3.0 and 16.6 ± 2.3 days per year, respectively (p = 0.8). The results
remained similar when patients with and without beta-blocker treatment were separately analyzed.
Conclusion: Our study demonstrates that the `1-adrenergic receptor polymorphism is not related to
cardiovascular disease in PD patients. Nevertheless, the low prevalence of mutant CC genotype in new PD
patients suggests that PD patients represent a highly biased population. [Hong Kong J Nephrol 2008;10(2):
58–63]
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INTRODUCTION
End-stage renal disease (ESRD) is one of the most
debilitating chronic medical illnesses. In Hong Kong,
there were more than 2,500 patients on long-term
dialysis in 1997 [1]. Peritoneal dialysis (PD) is the
preferred mode of renal replacement therapy in Hong
Kong, and accounts for 80% of patients requiring
dialysis [1].
Cardiovascular disease is the major cause of
mortality and morbidity in PD patients [2,3]. In addition
to the classic risk factors of atherosclerosis such as
diabetes, hypertension and hyperlipidemia, uremia and
possibly the dialysis procedure per se play important
roles in the pathogenesis of accelerated atherosclerosis
in renal failure patients [4]. However, the pathogenesis
of cardiovascular disease in dialysis patients remains
incompletely understood.
Recently, a polymorphism found in `1-adrenergic
receptor, which was first identified by Mason et al [5],
has been implicated as a potent genetic determinant of
hypertension and heart failure [6]. Individuals
homozygous for this potent and very common [7,8]
gain-of-function polymorphism at amino acid position
389 (arginine substituted for glycine) show increased
heart responsiveness to adrenergic receptor stimulation
[9]. Individuals with this polymorphism are predisposed
to heart failure by instigating hyperactive signaling
programs leading to depressed receptor coupling and
ventricular dysfunction, and which influences the
therapeutic response to beta-blockers [10]. These
individuals also have enhanced risks of developing
hypertension [8] and possibly myocardial infarction
[11].
Several lines of evidence indicate the presence of a
sympathetic hyperactivity in renal failure patients [12,
13], which is related to arterial hypertension and
atherosclerosis. It is suggested that diseased kidneys
send afferent nervous signals to central integrative
sympathetic nuclei,  thus contributing to the
development and maintenance of arterial hypertension
[14]. However, the relation between `1-adrenergic
receptor and cardiovascular disease in renal failure
patients has not been studied. In the present study, we
examined the relationship between `1-adrenergic
receptor polymorphisms and cardiovascular disease in
PD patients.
PATIENTS AND METHODS
Study population
We studied 189 consecutive new PD patients. We
excluded patients who planned to have elective living
donor transplant or transfer to another renal center
within 6 months.  The presence of diabetes,
hypertension, and a history of cardiovascular disease
were recorded. Hypertension was defined according to
the Joint National Committee VII criteria [15]. Blood
pressure, number of antihypertensive agents, and the
use of beta-blocker for all reasons were recorded. The
definition of cardiovascular disease used was as
previously described [16], which included angina, class
III to IV congestive heart failure, a history of previous
myocardial infarction, cerebrovascular accident, or
amputation for vascular disease.
Polymorphism detection
Genomic DNA was extracted from whole blood
samples by standard techniques. The method of
polymorphism detection has been described previously
[7,11]. Briefly, polymerase chain reaction analysis was
performed with 200 ng DNA as template in a final
volume of 50 +L. The primer pair used to amplify the
DNA was 5’-CGC TCT GCT GGC TGC CCT TCT
TCC-3’ (sense) and 5’-TGG GCT TCG AGT TCA CCT
GCT ATC-3’ (antisense), as described by Maqbool et
al [7] for the given polymorphism site. Amplified DNA
was digested with restriction endonuclease Bcg I (New
England Biolabs, Beverly, MA, USA). After restriction
enzyme digestion of the amplified DNA, genotypes
were identified by electrophoresis on 1.5% agarose gels
and visualized with ethidium bromide staining
ultraviolet illumination.
Clinical follow-up
All patients were planned to be followed for at least 2
years. The clinical management and dialysis regimen
were decided by individual nephrologist and not
affected by the study. The primary end point was a
composite one that consisted of cardiovascular death,
non-fatal myocardial infarction or stroke, hospital
admission for unstable angina, coronary intervention,
congestive heart failure, transient ischemic attack, or
lower limb ischemia. Secondary end points included
duration of hospitalization (all-cause) and all-cause
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mortality. Censoring events for survival analysis
included transfer to long-term hemodialysis, kidney
transplant, recovery of renal function, loss to follow-
up, and transfer to other dialysis centers.
Statistical analysis
Statistical analysis was performed using SPSS version
10.0 software (SPSS Inc., Chicago, IL, USA) for
Windows. Data were expressed as mean ± standard
deviation. Hardy-Weinberg equilibrium was calculated
by the standard method with the r2 test. Comparisons
of the prevalence of hypertension and pre-existing
cardiovascular disease between genotype groups were
performed by the r2 test, Student’s t test or one-way
analysis of variance as appropriate. Kaplan-Meier
analysis and the log rank test were used to explore the
effect of `1-adrenergic receptor genotype on the
composite cardiovascular end point as well as the
actuarial patient survival. A p value below 0.05 was
considered statistically significant. All probabilities
were two-tailed.
RESULTS
We studied 189 consecutive new PD patients. Their
demographic and baseline clinical information are
summarized in Table 1. Amongst the 189 patients, 181
(95.8%) had pre-existing hypertension, and 71 (37.6%)
had underlying cardiac or vascular disease before
initiation of dialysis.
Genotype and pre-existing vascular disease
Of the 189 patients, 66 (34.9%) had GG, 122 (64.6%)
had GC, and only 1 (0.5%) had CC genotype. The
values predicted by the assumption of the Hardy-
Weinberg equilibrium in the whole group of studied
subjects (GG, GC and CC groups are 46.2%, 44.1%
and 10.8%, respectively) were significantly different
from those that were observed (r2 test, p < 0.0001),
indicating that the studied subjects represented a highly
biased population. For the convenience of analysis,
patients were categorized into GG and GC/CC groups.
The prevalence of pre-existing vascular disease, use
of cardioprotective medications, peritoneal transport
characteristics, dialysis adequacy and nutritional status
were comparable between the genotype groups (Table
2). During the study period, the average systolic blood
pressure was 145.7 ± 20.7 mmHg, diastolic blood
pressure was 77.1 ± 13.7 mmHg, total cholesterol was
5.1 ± 1.3 mmol/L, triglyceride was 2.0 ± 1.3 mmol/L,
low-density lipoprotein cholesterol was 2.8 ± 1.5 mmol/
L, and HbA1c (for diabetic subjects) was 6.5 ± 1.2%.
There was no significant difference in blood pressure,
serum lipid or diabetic control between genotype groups
during the study period (details not shown). There were
39.4% and 36.6% patients of the GG and GC/CC
groups, respectively, with pre-existing cardiac or
vascular disease (p = 0.4). There were marginally more
patients with previous cerebrovascular disease in the
GG than in the GC/CC group (13 in 66 vs. 10 in 123
cases, p = 0.034 without adjustment for multiple
comparison).
Clinical outcome
The average follow-up was 30.2 ± 17.7 months. Eighty-
seven (46.0%) patients developed the primary
composite end point. The events contributing to the
primary composite end point were fatal myocardial
infarction (7 cases), fatal stroke (1 case), non-fatal
myocardial infarction (6 cases), non-fatal stroke
(7 cases), hospitalization for congestive heart failure
(53 cases), and hospitalization for acute coronary
syndrome (13 cases). The event-free survival was
63.6% and 71.5% at 24 months for GG and GC/CC
genotypes, respectively (p = 0.26) (Figure 1).
During the follow-up period, 62 (32.8%) patients
died. The causes of death were myocardial infarction
(11 cases), sudden cardiac death (11 cases),
cerebrovascular accident (5 cases), peripheral vascular
disease (1 case), peritonitis (10 cases), non-peritonitis
infection (10 cases), termination of dialysis (5 cases),
malignancy (3 cases), liver failure (2 cases), and other
specific causes (4 cases). During the study period, 30
patients had kidney transplantation, 15 changed to
hemodialysis for peritoneal failure, and five were
transferred to other centers. The actuarial patient
survival was 80.2% and 85.1% at 24 months for GG
and GC/CC genotypes, respectively (p = 0.53) (Figure
2). There was no difference in cardiovascular mortality
between the groups (details not shown).
During the follow-up period, there were 959 hospital
admissions, with a total of 5,658 days of hospitalization.
The number of hospital admissions for all causes was
similar between the GG and GC/CC groups (2.34 ±
0.36 vs. 2.73 ± 0.34 admissions per year, p = 0.3). The
duration of hospitalization for all causes was 15.9 ±
Table 1. Baseline clinical and demographic data in 189 patients
Sex (M:F) 95:94
Age (yr) 56.2 ± 14.8
Body height (m) 1.60 ± 0.09
Body weight (kg) 59.0 ± 12.3
Renal diagnosis, n (%)
Glomerulonephritis 55 (29.1)
Diabetic nephropathy 75 (39.7)
Polycystic kidney 8 (4.2)
Hypertensive nephrosclerosis 9 (4.8)
Obstructive uropathy 9 (4.8)
Others/unknown 33 (17.5)
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3.0 and 16.6 ± 2.3 days per year for the GG and GC/
CC groups, respectively (p = 0.8). The results remained
similar when patients with and without beta-blocker
treatment were separately analyzed, and when
hospitalizations for cardiac cause were separately
analyzed (details not shown).
Table 2. Comparison of baseline blood pressure, pre-existing vascular disease, peritoneal transport, dialysis adequacy and nutritional status
between the genotype groups
GG (n = 66) GC / CC (n = 123)
Blood pressure (mmHg)
Systolic 143.6 ± 25.6 146.9 ± 23.3
Diastolic 76.5 ± 14.0 80.1 ± 13.4
Cardioprotective medication, n (%)
Beta-blocker 28 (42.4) 53 (43.1)
Aspirin 16 (24.2) 34 (27.6)
ACE inhibitor or ARB 28 (42.4) 58 (47.2)
Statin 15 (22.7) 37 (30.1)
Pre-existing vascular disease, n
Hypertension 65 116
Coronary heart disease 11 25
Congestive heart failure 15 23
Cerebrovascular disease 13 10
Peripheral vascular disease 1 4
Peritoneal transport
D/P creatinine at 4 hr 0.62 ± 0.15 0.61 ± 0.13
MTAC creatinine (mL/min/1.73 m2) 9.54 ± 4.24 8.95 ± 4.75
Dialysis adequacy and nutritional status
Weekly total Kt/V 1.97 ± 0.52 2.06 ± 0.57
Residual GFR (mL/min/1.73 m2) 2.93 ± 2.19 3.16 ± 2.87
Serum albumin (g/L) 27.2 ± 4.1 29.1 ± 5.2
NPNA (g/kg/day) 1.05 ± 0.18 1.08 ± 0.31
FEBM (%) 42.9 ± 11.6 46.5 ± 14.1
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; D/P = dialysate-to-plasma ratio; MTAC = mass transfer area
coefficient; GFR = glomerular filtration rate; NPNA = normalized protein nitrogen appearance; FEBM = fat-free edema-free body mass.
Figure 1. Kaplan-Meier estimates of event-free survival of patients
with GG and GC/CC genotypes. Log rank test, p = 0.26.
Figure 2. Kaplan-Meier estimates of actuarial survival of patients
with GG and GC/CC genotypes. Log rank test, p = 0.53.
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DISCUSSION
Although `1-adrenergic receptor polymorphism is
widely implicated as a potent genetic determinant of
hypertension and cardiovascular disease in the general
population [5–11], we found no difference in the
incidence of cardiovascular events, all-cause mortality
or hospitalization in new PD patients between the
genotype groups. The reason for our negative results is
not clear. The sample size in our study was determined
a priori and was designed to achieve an 80% power to
detect a 25% absolute difference in the incidence of
the primary composite end point, and may not have
been adequate to detect a small effect of the
polymorphism. On the other hand, it is possible that
renal failure patients have overwhelming sympathetic
hyperactivity [12,13] that does not depend on the
activity of `1-adrenergic receptor. It should be noted
that although our study focused on PD patients,
peritoneal dialysis is the first line renal replacement
therapy in Hong Kong [1,17] and our study population
is therefore a cohort of unselected new dialysis patients.
It is important to note that hospital admission for
congestive heart failure was the most common cause of
the composite primary end point, and accounted for over
60% of the cases. Although `1-adrenergic receptor
polymorphism is associated with ventricular dysfunction
and heart failure in subjects with normal renal function
[10], the relation may not be present in dialysis patients.
More importantly, it is often difficult to distinguish
genuine ventricular failure in PD patients from fluid
overload secondary to ultrafiltration or compliance
problem. The Kaplan-Meier analysis of the primary
composite end point remained insignificant if admission
for congestive heart failure was not considered as an event
(details not shown). However, it is important to note that
there might be too few events after congestive heart
failure was excluded, making the result insignificant.
Theoretically, objective criteria that follow the ventricular
function, such as systolic and diastolic heart function by
echocardiography, may be more reliable. Unfortunately,
these measures are not available due to the limitation of
the original design of the study.
In the present study, we did not adjust for the degree
of blood pressure control during survival analysis.
Nevertheless, the prevalence of pre-existing
hypertension was high but similar between genotype
groups. It remains unknown whether the effect of `1-
adrenergic receptor polymorphisms on cardiovascular
disease is due to a difference in prevalence and/or
severity of hypertension, or a direct effect of altered
sympathetic drive onto the myocardium and
vasculature. Bengtsson et al [8] reported that individuals
homozygous for the Arg389 allele of the `1-adrenergic
receptor gene were at increased risk of developing
hypertension, but there was only one case with this
genotype in our study. However, subjects with
heterozygous Arg389 allele apparently did not have a
higher prevalence of hypertension [8] but were still
predisposed to congestive heart failure [10] and
myocardial infarction [11].
We found no difference in the incidence of
cardiovascular events between the genotype groups
when patients with and without beta-blocker therapy
were separately analyzed. It is possible that our
sample size was not sufficient for subgroup analysis.
Several studies found that `1-adrenergic receptor
polymorphisms are important determinants of
antihypertensive response to metoprolol [18,19],
although the relation is not unanimously agreed [20].
In mice, hemodynamic responses to beta-blocker were
greater in Arg389 strain [10]. Homozygosity for Arg389
was associated with improvement in ventricular
function during carvedilol treatment in heart failure
patients [10]. Taken together, the cardiovascular effect
of the `1-adrenergic receptor gene polymorphism
probably has an intricate interaction with beta-blocker
treatment, the effect of which probably needs a large
study to delineate.
We found that the distribution of `1-adrenergic
receptor genotype of our PD patients differed
significantly from the values predicted by the assumption
of the Hardy-Weinberg equilibrium. In our study, the
Arg389 (i.e. C) allele was present in 65% of the PD
patients, which is similar to the prevalence of 75% as
reported by Xie et al [21] in a Chinese population. The
highly skewed genotype distribution in our PD patients
is, therefore, not a result of a lower frequency of the
Arg389 allele but the distinct rarity of homozygous CC
subjects. The explanation is not entirely clear, but there
are two possibilities: either the CC genotype is protective
for renal failure, or these patients have a high mortality
before they progress to a dialysis-dependent state.
In summary, our study shows that the ` 1-adrenergic
receptor polymorphism is not related to cardiovascular
disease in PD patients. Nevertheless, the low prevalence
of the mutant CC genotype in new PD patients suggests
that PD patients represent a highly biased population.
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